Compugen reported $90.6M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Arca Biopharma USD 49.52M 2.58M Mar/2026
aTyr Pharma USD 10.01M 735K Mar/2026
Bio Path 13.65M 3.37M Sep/2022
Brainstorm Cell Therapeutics USD 15K 14K Mar/2026
Cara Therapeutics USD 20.73M 684K Dec/2025
Clal Biotechnology ILS 5.73M 1.71M Dec/2023
Compugen USD 90.6M 83.14M Dec/2025
Immunic USD 186.63M 171.15M Mar/2026
Infinity Pharmaceuticals USD 17.75M 7.99M Jun/2023
Minerva Neurosciences USD 82.3M 70.02M Dec/2025
RedHill Biopharma USD 2.87M 1.75M Jun/2025
TherapeuticsMD 523K 89K Jun/2024